Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140244 · ClinicalTrials.gov registry record · Phase 2
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00140244 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT00140244, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether replacing leptin to normal levels can reverse the changes in fat distribution, lipid profile, and other metabolic problems associated with highly active antiretroviral therapy (HAART)-induced lipodystrophy and metabolic syndrome in HIV patients.
Interventions
- DRUG Placebo
- DRUG r-metHuLeptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2001-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140244
The ClinicalTrials.gov registry entry for NCT00140244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00140244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140244 about?
NCT00140244 is a clinical study titled "Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome". The purpose of this study is to examine whether replacing leptin to normal levels can reverse the changes in fat distribution, lipid profile, and other metabolic problems associated with highly active antiretroviral therapy (HAART)-induced lipodystrophy and metabolic syndrome in HIV patients.
What is the current status of trial NCT00140244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2001-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00140244?
The interventions under investigation include: Placebo (DRUG), r-metHuLeptin (DRUG).
Who is sponsoring clinical trial NCT00140244?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.